Risk of Poor Neonatal Adaptation Syndrome Among Infants Exposed to Second-Generation Atypical Antipsychotics Compared to Antidepressants: Results From the National Pregnancy Registry for Psychiatric Medications

Adele C. Viguera, MD; Sara A. McElheny, BA; Phoebe S. Caplin, BA; Lauren A. Kobylski, MPH; Ella T. Rossa, BA; Amanda V. Young, BA; Peter Gaccione, MA; Lina Góez-Mogollón, MD; Marlene P. Freeman, MD; Lee S. Cohen, MD

J Clin Psychiatry 2023;84(1):22m14492

ABSTRACT

Objective: While poor neonatal adaptation syndrome (PNAS) has been particularly well described among infants exposed to antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), this is not the case for second-generation antipsychotics (SGAs). In 2011, the US Food and Drug Administration (FDA) issued a drug safety warning regarding fetal antipsychotic exposure and risk for PNAS and extrapyramidal symptoms (EPS). The primary objective of this study was to examine the risk for PNAS among infants exposed to SGAs compared to SSRI/SNRI-exposed infants, leveraging the prospective, longitudinal design of the National Pregnancy Registry for Psychiatric Medications (NPRPM).

Methods: The NPRPM is a prospective pharmacovigilance program in which pregnant women, aged 18–45 years, are enrolled and followed prospectively. Medical records were systematically reviewed and data abstracted using a checklist of PNAS and EPS symptoms specifically outlined in the FDA drug safety warning. The two study groups included infants exposed to an SGA during pregnancy and infants exposed to an SSRI/SNRI during pregnancy. The primary outcome was the presence of at least one or more PNAS symptoms during the first month of life. Other neonatal outcomes following exposure to the medication of interest, including preterm birth, neonatal intensive care unit (NICU) admission, rates of EPS, and whether infants were discharged home with their mothers, are also reported.

Results: Of the 2,145 women enrolled in this study as of December 16, 2020, a total of 373 women and their infants (n = 384) were eligible for inclusion (n = 193 SGA-exposed infants and 191 SSRI/SNRI-exposed infants). Among SGA-exposed infants, 32.6% (63/193) experienced at least 1 PNAS sign compared to 34.6% of infants (66/191) in the SSRI/SNRI-exposed group. The majority of infants in each group showed no symptoms of PNAS. No differences were observed between the two groups with respect to rates of preterm birth, NICU admission, prevalence of EPS, and timing of infants being discharged home with their mothers.

Conclusions: PNAS symptomatology was comparable among infants exposed prenatally to an SGA or to an SSRI/SNRI. These preliminary findings provide an estimated risk of PNAS among infants exposed to SGAs of roughly 30%. Interestingly, these findings are also consistent with estimates in the literature of PNAS in SSRI/SNRI-exposed infants, suggesting a possible common pathway underlying this phenomenon.

Trial Registration: ClinicalTrials.gov identifier: NCT01246765

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (58)

Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat. 2013;9:1257–1266. PubMed CrossRef
Jansson LM, Patrick SW. Neonatal abstinence syndrome. Pediatr Clin North Am. 2019;66(2):353–367. PubMed CrossRef
Kautzky A, Slamanig R, Unger A, et al. Neonatal outcome and adaption after in utero exposure to antidepressants: a systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145(1):6–28. PubMed CrossRef
Convertino I, Sansone AC, Marino A, et al. Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects. Drug Saf. 2016;39(10):903–924. PubMed CrossRef
Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf. 2014;5(2):100–109. PubMed CrossRef
Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372–2383. PubMed CrossRef
Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e309–e320. PubMed CrossRef
Hendson L, Shah V, Trkulja S. Selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors in pregnancy: infant and childhood outcomes. Paediatr Child Health. 2021;26(5):321–322. PubMed CrossRef
McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468–2479. PubMed CrossRef
Kieviet N, Hoppenbrouwers C, Dolman KM, et al. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. Acta Paediatr. 2015;104(4):384–391. PubMed CrossRef
Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156(11):1129–1132. PubMed CrossRef
Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60(7):720–726. PubMed CrossRef
Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158(4):312–316. PubMed CrossRef
Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65(2):230–237. PubMed CrossRef
Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173–176. PubMed CrossRef
Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898–906. CrossRef
Davis RL, Rubanowice D, McPhillips H, et al; HMO Research Network Center for Education, Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):1086–1094. PubMed CrossRef
Ferreira E, Carceller AM, Agogué C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119(1):52–59. PubMed CrossRef
Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate’s clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol. 2008;28(3):334–339. PubMed CrossRef
Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG. 2008;115(2):283–289. PubMed CrossRef
Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry. 2009;43(9):846–854. PubMed CrossRef
Galbally M, Spigset O, Johnson AR, et al. Neonatal adaptation following intrauterine antidepressant exposure: assessment, drug assay levels, and infant development outcomes. Pediatr Res. 2017;82(5):806–813. PubMed CrossRef
Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42(3):95–100. PubMed CrossRef
Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113(2):368–375. PubMed CrossRef
Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry. 2007;164(8):1206–1213. PubMed CrossRef
Suri R, Hellemann G, Stowe ZN, et al. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry. 2011;72(7):1002–1007. PubMed CrossRef
Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010–1015. PubMed CrossRef
Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009;163(10):949–954. PubMed CrossRef
Yang A, Ciolino JD, Pinheiro E, et al. Neonatal discontinuation syndrome in serotonergic antidepressant-exposed neonates. J Clin Psychiatry. 2017;78(5):605–611. PubMed CrossRef
Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–462. PubMed CrossRef
Vigod SN, Gomes T, Wilton AS, et al. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298. PubMed CrossRef
Hatters Friedman S, Moller-Olsen C, Prakash C, et al. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int J Psychiatry Med. 2016;51(6):521–533. PubMed CrossRef
Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–1220. CrossRef
Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007;30(3):247–264. PubMed CrossRef
Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7):e003062. PubMed CrossRef
Brunner E, Falk DM, Jones M, et al. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013;14(1):38. PubMed CrossRef
Kulkarni J, Worsley R, Gilbert H, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9(5):e94788. PubMed CrossRef
Petersen I, McCrea RL, Sammon CJ, et al. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health Technol Assess. 2016;20(23):1–176. PubMed CrossRef
Ellfolk M, Leinonen MK, Gissler M, et al. Second-generation antipsychotics and pregnancy complications. Eur J Clin Pharmacol. 2020;76(1):107–115. PubMed CrossRef
Administration UFD. Safety Report Updates. Administration UFD. Safety Report Updates. https://www.fda.gov/science-research/pediatrics/safety-report-updates. Accessed April 15, 2022.
Salisbury AL, O’Grady KE, Battle CL, et al. The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month. Am J Psychiatry. 2016;173(2):147–157. Published online Oct 30, 2015. PubMed CrossRef
Administration UFD. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-antipsychotic-drug-labels-updated-use-during-pregnancy-and-risk. Accessed April 15, 2022.
Cohen LS, Viguera AC, McInerney KA, et al. Establishment of the National Pregnancy Registry for atypical antipsychotics. J Clin Psychiatry. 2015;76(7):986–989. PubMed CrossRef
Cohen LS, Viguera AC, McInerney KA, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for atypical antipsychotics. Am J Psychiatry. 2016;173(3):263–270. PubMed CrossRef
Viguera AC, Freeman MP, Góez-Mogollón L, et al. Reproductive safety of second-generation antipsychotics: updated data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry. 2021;82(4):20m13745. PubMed CrossRef
Fraser J, Walls M, McGuire W. Respiratory complications of preterm birth. BMJ. 2004;329(7472):962–965. PubMed CrossRef
Malm H, Sourander A, Gissler M, et al. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data. Am J Psychiatry. 2015;172(12):1224–1232. PubMed CrossRef
McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444–449, quiz 546. PubMed CrossRef
Eke AC, Saccone G, Berghella V. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis. BJOG. 2016;123(12):1900–1907. PubMed CrossRef
Huybrechts KF, Sanghani RS, Avorn J, et al. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One. 2014;9(3):e92778. PubMed CrossRef
Huang H, Coleman S, Bridge JA, et al. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36(1):13–18. PubMed CrossRef
Terrana N, Koren G, Pivovarov J, et al. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2015;35(5):559–565. PubMed CrossRef
Braun D, Braun E, Chiu V, et al. Trends in neonatal intensive care unit utilization in a large integrated health care system. JAMA Netw Open. 2020;3(6):e205239. PubMed CrossRef
Lee HC, Bennett MV, Schulman J, et al. Estimating length of stay by patient type in the neonatal intensive care unit. Am J Perinatol. 2016;33(8):751–757. PubMed CrossRef
Administration UFD. Pregnancy Registries. FDA.gov website. https://www.fda.gov/science-research/womens-health-research/pregnancy-registries.
Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157(2):179–184. PubMed CrossRef
Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–1824, quiz 1923. PubMed CrossRef
Cohen LS, Nonacs RM, Bailey JW, et al. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Women Ment Health. 2004;7(4):217–221. PubMed CrossRef